Selection of Licensed Compounds for Development. Novartis shall have the sole right to select Licensed Compounds for development into Licensed Products, to discontinue development of Licensed Products, to substitute new or back-up Licensed Products for discontinued ones, to control the Development thereof, and to hold all Drug Approval Applications and obtain and hold all Regulatory Approvals with respect thereto on a worldwide basis, subject to the obligations of diligence set forth in this Section 3.
Appears in 5 contracts
Samples: Collaboration Agreement, Collaboration Agreement (Discovery Partners International Inc), Collaboration Agreement (Infinity Pharmaceuticals, Inc.)
